Future preclinical studies may provide a rationale for blocking the JNK signaling pathway in DCs of metastatic breast cancer patients to reduce impaired DC-mediated immune responses, and also may suggest new insight in understanding the effects of the tumor microenvironment on immune responses. Here, MAPK8 is linked to breast cancer.